Skip to main content

Table 1 Patients’ characteristics depending on the plasma AGE-related fluorescence (FL).a

From: Prognostic Potential and Tumor Growth-Inhibiting Effect of Plasma Advanced Glycation End Products in Non-Small Cell Lung Carcinoma

NSCLC patients parameter   Plasma FL  
Data Lowb (n = 36) Highb (n = 34) P valuec
Plasma FL, μg/mL AGE-BSA M 0.81 (0.73–0.95) 1.29 (1.21–1.61) <0.001
Age, y M 69 (60–72) 68 (60–73) 0.797
Gender     
Male n 31 22 0.071
Female n 5 12  
Body mass index M 26 (24–28) 27 (24–29) 0.813
NSCLC histology     
ADCd n 11 19 0.059
SCCe n 21 12  
Others n 4 4  
Tumor (T) stage     
T1 n 5 12 0.113
T2 n 20 14  
T3-4 n 11 8  
Nodal (N) stage     
N0 n 15 21 0.290
N1 n 9 6  
N2 n 11 7  
Resection (R) stage     
R0 n 31 33 0.199
R1 n 5 1  
Smoker     
Current n 18 12 0.199
Former n 12 16  
None n 6 6  
Diabetes mellitus     
Yes n 10 9 1.000
No n 26 29  
Blood glucose, mmol/L M 5.5 (4.9–7.0) 5.3 (4.9–6.9) 0.812
Renal failure     
Yes n 3 4 1.000
No n 33 30  
Blood creatinine, μmol/L M 79 (69–85) 77 (70–85) 0.897
Blood urea, mmol/L M 5.3 (4.6–6.5) 5.7 (4.6–6.3) 0.668
  1. aData are either given as median (M) with interquartile range or as number of NSCLC patients (n).
  2. bCutoff point at the median plasma FL of all NSCLC patients (1.08 µg/mL AGE-BSA).
  3. cP values were calculated by use of the Student t test (median differences) or the χ2 test (homogeneity of variances) as appropriated.
  4. dADC, adenocarcinoma.
  5. eSCC, squamous cell carcinoma.